Loss of endothelial barrier function can lead to increased endothelial permeability, which results in an anarchical movement of fluid, solutes, and cells outside the vasculature and into the surrounding tissues [ 2], thereby contributing to various diseases such as cancer [ 3], atherosclerosis [ 4], lung injury [ 5], kidney injury [ 6], stroke, and many other diseases [ 7].
Whether such strategies to improve lung function can result in failure of the alveolar capillary barrier and promote transient bacterial translocation in humans remains unknown.
When ROS-induced damage reaches critical levels or cannot be dealt with appropriately, the barrier function can become severely impaired, resulting in uncontrolled fluid leak, a dysregulated immune response, cell death, and tissue damage.
Another advantage of this experimental setup is that barrier function can be monitored in parallel.
6 8 This barrier function can easily be disrupted during mucosal inflammation.
This decreased barrier function can be exploited to achieve direct nose-to-brain drug delivery.
There is now increasing evidence for the notion that loss of intestinal barrier functions can occur either abruptly, e.g. following a major trauma resulting in gram-negative sepsis and multi-organ failure (MOF), or gradually leading to chronic inflammatory diseases.
Disruptions in either the intestinal mucus or epithelial barrier can result in pathogenic bacterial translocation.
This affirms other studies that find barriers to entry can result from financial regulation.
And as Australia's Great Barrier Reef has shown, bleaching can result in serious mortality.
